Moolec ScienceMLEC -0.26%46 Return-on-Tangible-Asset is 173.41% as of Dec. 2025. GuruFocus rates MLEC with a GF Score™ of 46/100 and a GF Value™ of $84.84 (Possible Value Trap). The stock has 9 warning signs investors should review. Among 1,412 Biotechnology companies, Moolec Science ranks better than 66.01% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Moolec Science's annualizedNet Income for the quarter that ended in Dec. 2025 was $137.9 Mil. Moolec Science's average total tangible assets for the quarter that ended in Dec. 2025 was $79.5 Mil. Therefore, Moolec Science's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 173.41%.
The historical rank and industry rank for Moolec Science's Return-on-Tangible-Asset or its related term are showing as below:
MLEC'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -381.38 Med: -18.96 Max: 493.94
Current: -15.56
During the past 5 years, Moolec Science's highest Return-on-Tangible-Asset was 493.94%. The lowest was -381.38%. And the median was -18.96%.
MLEC's Return-on-Tangible-Asset is ranked better than 66.01% of 1412
companies
in the Biotechnology industry
Industry Median: -35.66
vs MLEC: -15.56
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Moolec Science Return-on-Tangible-Asset Related Terms
Moolec Science Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Moolec Science's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLEC vs GNPX, ADIL, APVO: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Moolec Science's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moolec Science Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moolec Science's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Moolec Science's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 173.41% mean?
Moolec Science (MLEC) has a Return-on-Tangible-Asset of 173.41% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Moolec Science and its competitors. According to the industry distribution chart, Moolec Science ranks #480 out of 1412 companies in the Biotechnology industry, placing it in the top 34%.
Is Moolec Science's Return-on-Tangible-Asset too high?
Moolec Science's current Return-on-Tangible-Asset is 173.41%. Based on the distribution chart, Moolec Science ranks #480 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Moolec Science has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Moolec Science's Return-on-Tangible-Asset compare to GNPX and ADIL?
According to the Biotechnology industry distribution chart, Moolec Science ranks #480 out of 1412 companies for Return-on-Tangible-Asset. This puts Moolec Science in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Moolec Science and its competitors. Moolec Science's current Return-on-Tangible-Asset is 173.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moolec Science stock overvalued right now?
Based on GuruFocus' analysis, Moolec Science (MLEC) is currently considered Possible Value Trap. The stock's GF Value™ is $84.84, compared to a current price of $7.69 — trading 90.9% below its estimated fair value. The current Return-on-Tangible-Asset is 173.41%. Moolec Science's overall GF Score™ is 46/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Moolec Science (MLEC), the current Return-on-Tangible-Asset is 173.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moolec Science (MLEC) Overvalued in 2026?
Based on GuruFocus' analysis, Moolec Science stock appears to be undervalued.
The current stock price of $7.69 is trading 90.9% below its estimated GF Value™ of $84.84.
GuruFocus considers Moolec Science to be Possible Value Trap.
Key valuation signals for MLEC:
Return-on-Tangible-Asset: 173.41%
GF Value™: $84.84 vs. price of $7.69 (90.9% below fair value)
No single metric tells the full story. See the MLEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
46GF Score
Get the complete analysis for MLEC
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLEC has been successfully added to your 
